Bank of Montreal
GEVA

Bank of Montreal’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Bank of Montreal’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-530
Closed -$56K – 4828
2014
Q2 		$56K Buy
+530
New +$45.1K ﹤0.01% 3151
2014
Q1 		– Sell
-5
Closed – – 4256
2013
Q4 		$0 Sell
5
-6,181
-100% -$367K ﹤0.01% 4077
2013
Q3 		$392K Buy
6,186
+5
+0.1% +$246 ﹤0.01% 1922
2013
Q2 		$259K Buy
+6,181
New +$282K ﹤0.01% 2070

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Bank of Montreal's GEVA Position: Q3 2014 in Review

Bank of Montreal sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q3 2014, closing a stake of 530 shares — an estimated $56K sold.

Bank of Montreal first reported a position in GEVA in Q2 2013 and held it in 4 quarters. The position peaked at $392K in Q3 2013. 120 funds tracked by Wall St. Rank hold GEVA as of Q3 2014.

  • Bank of Montreal reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q3 2014 after selling out during the quarter.
  • Bank of Montreal sold 530 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q3 2014, an estimated $56K.
  • Bank of Montreal first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 4 quarters.
  • Bank of Montreal's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $392K in Q3 2013.
  • 120 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q3 2014.

Based on Bank of Montreal's 13F filing for Q3 2014, filed 7 Nov 2014.